Hologic (NASDAQ:HOLX) Price Target Raised to $70.00 at Mizuho

Hologic (NASDAQ:HOLX - Free Report) had its price target upped by Mizuho from $65.00 to $70.00 in a research note published on Wednesday morning,Benzinga reports. They currently have an outperform rating on the medical equipment provider's stock.

A number of other brokerages have also recently issued reports on HOLX. Evercore ISI lifted their target price on Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a report on Tuesday, July 8th. Morgan Stanley lowered their price target on Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a report on Monday, May 5th. Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Stephens lowered their price target on Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a report on Tuesday, May 13th. Finally, Royal Bank Of Canada lowered their price target on Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a report on Friday, May 2nd. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $77.33.

Hologic Price Performance

Shares of HOLX traded down $0.14 during midday trading on Wednesday, reaching $63.88. The stock had a trading volume of 462,039 shares, compared to its average volume of 2,378,700. Hologic has a 52 week low of $51.90 and a 52 week high of $84.67. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.24 and a quick ratio of 2.52. The firm's 50 day moving average price is $62.31 and its 200-day moving average price is $63.30. The company has a market capitalization of $14.24 billion, a P/E ratio of 26.96, a P/E/G ratio of 2.34 and a beta of 0.55.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The company's quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.03 EPS. On average, analysts forecast that Hologic will post 4.28 earnings per share for the current fiscal year.

Insider Buying and Selling at Hologic

In other Hologic news, Director Martin D. Madaus acquired 5,445 shares of the business's stock in a transaction that occurred on Wednesday, May 7th. The stock was acquired at an average price of $55.24 per share, with a total value of $300,781.80. Following the transaction, the director owned 5,445 shares of the company's stock, valued at approximately $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.88% of the company's stock.

Hedge Funds Weigh In On Hologic

Several large investors have recently made changes to their positions in the business. Greenleaf Trust lifted its position in shares of Hologic by 5.1% during the 2nd quarter. Greenleaf Trust now owns 3,579 shares of the medical equipment provider's stock worth $233,000 after purchasing an additional 173 shares during the last quarter. Beverly Hills Private Wealth LLC increased its stake in Hologic by 3.6% during the first quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider's stock valued at $320,000 after acquiring an additional 180 shares during the period. Allworth Financial LP increased its stake in Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after acquiring an additional 216 shares during the period. Dark Forest Capital Management LP increased its stake in Hologic by 7.9% during the fourth quarter. Dark Forest Capital Management LP now owns 3,053 shares of the medical equipment provider's stock valued at $220,000 after acquiring an additional 223 shares during the period. Finally, Baker Avenue Asset Management LP increased its stake in Hologic by 0.5% during the fourth quarter. Baker Avenue Asset Management LP now owns 42,051 shares of the medical equipment provider's stock valued at $3,031,000 after acquiring an additional 225 shares during the period. Institutional investors and hedge funds own 94.73% of the company's stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.